STRYKER CORP Group President Viju Menon reported a compensation-related stock award, not an open-market purchase. He acquired 9,320 shares of common stock at no cost as a grant tied to pre-established three-year adjusted diluted net earnings per share and sales performance goals.
The earned shares are scheduled to vest on March 21, 2026. Following this grant, Menon holds 21,831 shares directly and 198 shares indirectly through a 401(k) plan, giving a clearer picture of his overall equity stake in the company.
Stryker Corp President and COO Spencer S. Stiles reported an acquisition of 14,912 shares of Common Stock as a performance-based award. The shares were earned upon meeting pre-established three-year adjusted diluted net earnings per share and sales performance goals and will vest on March 21, 2026.
After this grant, Stiles directly holds 83,894 Stryker shares and has an additional 1,670 shares held indirectly through a 401(k) plan. This filing reflects executive compensation rather than an open-market stock purchase or sale.
Pierce James Andrew reported acquisition or exercise transactions in this Form 4 filing.
Stryker Corp Group President James Andrew Pierce reported an equity award of 14,912 shares of Common Stock. The shares were granted at no cash cost upon achievement of pre-set three-year earnings per share and sales goals and will vest on March 21, 2026.
After this grant, Pierce directly holds 88,246 common shares. He also reports indirect holdings of 712 shares held by "Son GP", 713 shares held by "Son AP", and 1,595 shares held through a 401(k) account as of the same date.
STRYKER CORP director Ronda E. Stryker reported a bona fide gift of 55,600 shares of common stock on behalf of a revocable trust. The trust held 2,231,173 shares after the gift. Additional indirect holdings were 12,857,163 shares in the L. Lee Stryker Trust and 37,600 shares in the 1988 William D. Johnston Trust, plus 560 shares held directly.
Stryker Corp director Ronda E. Stryker reported several indirect trust transactions in company common stock. A revocable trust associated with her made bona fide gifts of 377,900 shares on February 13, 2026 and 222,300 shares on February 17, 2026, both at a stated price of $0.00 per share.
Separately, on February 17, 2026, the L. Lee Stryker Trust, for which she serves as trustee and her children are beneficiaries, distributed 42,000 shares to beneficiaries’ individual trusts. She disclaims beneficial ownership of the L. Lee Stryker Trust holdings except to the extent of her pecuniary interest.
Greenleaf Trust reports beneficial ownership of 16,801,654 shares of Stryker Corp common stock, representing 4.4% of the class as of 12/31/2025. Greenleaf has sole voting power over 181,176 shares and shared voting power over 16,620,478 shares.
The firm has sole dispositive power over 122,825 shares and shared dispositive power over 16,678,829 shares. It holds these securities in a fiduciary capacity for various trust and investment management customers and states they are held in the ordinary course of business, not to change or influence control of Stryker.
Stryker Corporation reports strong 2025 growth as a global medical technology leader. Net sales reached $25.1 billion, up from $22.6 billion in 2024, led by MedSurg and Neurotechnology at $15.6 billion and Orthopaedics at $9.5 billion. Net earnings were $3.25 billion, or $8.40 diluted EPS.
The company completed roughly $5.0 billion of acquisitions, including Inari Medical, expanding its Vascular portfolio for venous thromboembolism treatment. Stryker invested $1.62 billion in research, development and engineering and ended the year with $4.10 billion in cash and equivalents and $15.9 billion of total debt.
Stryker issued new senior notes totaling $3.0 billion and expanded its revolving credit facility to $3.0 billion maturing in 2030. The company paid $1.28 billion in dividends and employed about 56,000 people worldwide as of December 31, 2025.
Stryker Corporation director Ronda E. Stryker, through a revocable trust, reported a series of open-market sales of Stryker common stock on February 4–5, 2026. The revocable trust sold multiple blocks of shares at weighted average prices ranging from $358.005 to $368.635 per share, as detailed in the footnotes. After these transactions, the revocable trust held 2,207,331 Stryker shares, with additional indirect holdings of 13,578,805 shares by the L. Lee Stryker Trust and 37,600 shares by the 1988 William D. Johnston Trust, plus 560 shares held directly.
Stryker Corporation reported an equity award transaction for VP and Chief Accounting Officer William E. Berry Jr. on February 4, 2026. He received a grant of 797 restricted stock units with no cash price per unit, increasing his directly held common stock to 3,602 shares, plus 615 shares held indirectly through a 401(k) plan.
Each RSU represents a contingent right to receive one share of Stryker common stock and is scheduled to vest in three equal installments on March 21, 2027, March 21, 2028, and March 21, 2029. Berry also received an employee stock option for 2,391 shares at an exercise price of $360.82, which becomes exercisable as to 20% of the option on each of the first five anniversaries of the grant date and expires on February 3, 2036.
Stryker Corporation reported that VP and Chief Commercial Officer Kimberly Ann Montagnino received an employee stock option grant on February 4, 2026. The option covers 1,830 shares of Stryker common stock at an exercise price of $360.82 per share.
The grant was issued under the Stryker Corporation 2011 Long-Term Incentive Plan and is exercisable as to 20% of the option on each of the first five anniversaries of the grant date. Following this award, she directly holds options for 1,830 shares.